Sankyo Company, Ltd. To Launch Osteoporosis Treatment Drug In Europe

Published: Jul 19, 2006

Tokyo, July 19, 2006 (JCN) - Daiichi Sankyo Europe GmbH, a wholly owned subsidiary of Sankyo Co. Ltd., have agreed with Eli Lilly on the launch of EVISTA (raloxifene), a new drug that helps prevent osteoporosis and can only be taken after menopause. Raloxifene is a selective estrogen receptor modulator, specifically developed to maintain beneficial estrogenic activity on bone and lipids and antiestrogenic activity on endometrial and breast tissue.

Back to news